# Novel Therapies, Residual Risk, Familial Hypercholesterolemia, and Digital Tools: Multispecialty Insights from a Dyslipidemia Management Survey

Article · Mesquita-Lousada A, Rocha-Melo-Sousa A, Teixeira C, Guimarães TR, Marques-Vieira M, Andrade JP, Ribeiro H, Neiva-Sousa M, Rocha-Neves J

- Archive id: doi:10.3390/jcm15114205
- Published: 2026-05-29
- Venue: Journal of clinical medicine
- DOI: https://doi.org/10.3390/jcm15114205
- PMID: 42279067
- PMCID: PMC13258806
- Citations: 0
- Source URL: https://doi.org/10.3390/jcm15114205
- PDF: https://europepmc.org/articles/PMC13258806/pdf
- Provenance: europepmc

## Abstract

Introduction/Objectives : Although contemporary cardiovascular guidelines endorse intensive low-density lipoprotein cholesterol (LDL-C) lowering and advanced lipid biomarkers for refined risk stratification, important gaps in knowledge and implementation persist. This study evaluated clinician familiarity with novel lipid-lowering therapies, approaches to residual cardiovascular risk, confidence in identifying familial hypercholesterolemia (FH), and perceived usefulness of digital decision-support tools. Methods : A multispecialty, cross-sectional online survey (October 2025) of physicians involved in dyslipidemia care was conducted. The questionnaire assessed familiarity, accessibility, and barriers regarding proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, inclisiran, and bempedoic acid; confidence and practice in managing complex populations and residual risk; confidence in detecting FH and expectations for lipoprotein(a) \[Lp(a)\]; and perceived value of digital decision-support and automated risk alerts. Descriptive statistics and chi-square tests were performed. Results : Ninety-five clinicians completed the survey, with the largest group (41.1%) being general practitioners. Of them, 20.0% reported familiarity with all three novel therapies, and 49.5% reported restricted access due to cost and reimbursement constraints. Overall confidence in managing dyslipidemia in complex populations was moderate. Of note, 31.6% did not routinely assess residual risk after achieving LDL-C targets. Among those who did, imaging-based evaluation of subclinical atherosclerosis was the most frequently selected approach, followed by Lp(a) and triglycerides, hs-CRP, and apoB. Confidence in recognizing FH was modest, and expectations regarding future Lp(a) testing differed across specialties. Most respondents endorsed integrated decision-support tools and automated risk-alert prompts. Conclusions : Implementation gaps persist in dyslipidemia care, while strong receptiveness to digital decision-support highlights an opportunity to align practice more closely with evidence-based recommendations.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [Cardiovascular Therapeutics](https://space-kitty.com/topics/cardiovascular-innovation)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.